StevenWaggonerMD

Gynecologic Oncology, Hospice & Palliative Medicine, Minimally Invasive / Endoscopic Surgery, Complementary and Integrative Medicine

Staff Gynecologic Oncologist, Cleveland Clinic. Professor, Lerner College of Medicine at Case Western Reserve University. Contact PI, NRG Oncology for Case Western Reserve University

Join to view full profile

Dr. Waggoner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Waggoner's full profile

Already have an account?

Office
9500 Euclid Avenue/A81
Cleveland, OH 44195
Phone+1 216-445-3410

Fax+1 216-444-8551

Summary

I am a Board Certified Gynecologic Oncologist specializing in the treatment of women with cancer or suspected cancer of the female reproductive system.

I am a surgeon and chemotherapy specialist (including HIPEC and immunotherapy) for women with cancer of the ovaries, tubes, uterus, cervix, vulva and vagina.

I assist women with genetic predisposition to gynecologic cancers on means of reducing this risk.

NIH funded clinical research through the NCTN has been a focus of my career for 30+ years. I currently serve as the contact Principal Investigator for NRG Oncology at Case Western Reserve University and its affiliates.

Additional professional interests of mine include cancer survivorship for women and caregivers, patient safety, and management of treatment related side effects.

Educating and mentoring students, residents, fellows and nurses in the specialty of Gynecologic Oncology is a vital part of my career.

Education & Training

Georgetown University HospitalFellowship, Gynecologic Oncology, 1988 - 1991
University of ChicagoResidency, Obstetrics and Gynecology, 1984 - 1988
University of Washington School of MedicineClass of 1984

Certifications & Licensure

OH State Medical License 2002 - 2025
IL State Medical License 1984 - 2008
MD State Medical License 1988 - 1991
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

“America’s Top Doctors” Citation (Castle Connolly) 2001-2023
University Hospitals Cleveland Medical Center Distinguished Physician Award 2019
Anderson Family Endowed Master Clinician in Gynecologic Oncology University Hospitals of Cleveland, 2015

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2012 Jul 09
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer Start of enrollment: 2013 Jun 05
Active, not recruiting
Not Applicable
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14
Terminated
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical T...
Ann H Klopp, Danielle Enserro, Matthew Powell, Marcus Randall, Julian C Schink
Journal of Clinical Oncology. 2024-07-10
1 citations
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Lilian T Gien, Danielle M Enserro, Matthew S Block, Steven Waggoner, Linda R Duska
Gynecologic Oncology. 2024-07-01
4 citations
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Leslie M Randall, David M O'Malley, Bradley J Monk, Robert L Coleman, Stephanie Gaillard
Gynecologic Oncology. 2023-11-01

Press Mentions

NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects CommitteeDecember 12th, 2022
Clinical Trial Underscores Promise of Immunotherapy, in Combination with Second Drug, for Ovarian CancerJuly 13th, 2019
Case Comprehensive Cancer Center Awarded $8.9 Million to Expand Access to Clinical TrialsMay 16th, 2019
Join now to see all